GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Autolus Therapeutics
Autolus is a biotech company developing next-generation CAR-T therapy for cancer treatment. Its stock price is a venture bet that its technology will prove safer and more effective than existing cell therapies.
Share prices of companies in the market segment - Oncology cell gene therapy
Autolus Therapeutics is a biopharmaceutical company developing a new generation of programmable T-cell therapy (CAR-T) for the treatment of oncological diseases, primarily blood cancers. We have classified it in the "Oncology Cell Gene Therapy" segment. The chart below shows the overall dynamics of this revolutionary, yet high-cost, biotech sector.
Broad Market Index - GURU.Markets
Autolus Therapeutics is a British biopharmaceutical company developing cutting-edge CAR-T cell therapy for the treatment of blood cancers. As a component of the GURU.Markets index, it represents the biotech sector. The chart below shows the US market. See how Autolus shares compare to the US market.
Change in the price of a company, segment, and market as a whole per day
AUTL - Daily change in the company's share price Autolus Therapeutics
Change_co for Autolus Therapeutics, an oncology company, reflects the extreme volatility associated with cell therapy development. Daily fluctuations indicate sensitivity to clinical trial results. This metric is important for analyzing biotech breakthroughs on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Oncology cell gene therapy
Autolus Therapeutics plc is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with the performance of AUTL, a pioneer in cell therapy, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Autolus is a biopharmaceutical company developing CAR-T cell therapy for cancer. The cell therapy sector is one of the most advanced and volatile in biotech. The chart below shows the average daily fluctuations in this industry, serving as a benchmark for evaluating Autolus's highly volatile stock.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Autolus Therapeutics
Autolus Therapeutics' year-to-date performance is a story of developing a new generation of CAR-T cell therapy for cancer. Its market capitalization over the next 12 months depends entirely on the clinical trial results of its lead candidate. Positive data could make it a leader in this complex but promising field of oncology.
Annual dynamics of market capitalization of the market segment - Oncology cell gene therapy
Autolus Therapeutics plc is a late-stage biotech developing cutting-edge CAR-T therapy for cancer treatment. Its stock performance is entirely dependent on clinical trial results and regulatory decisions. The chart reflects the enormous potential of its unique technology.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Autolus Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new cell therapy trials. The company's stock chart lives in a world of its own.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Autolus Therapeutics
The performance of Autolus, a biopharmaceutical company, is speculative. Monthly fluctuations on the chart reflect not revenue, but rather news about the progress of clinical trials of its innovative CAR-T cancer therapy, the success of which determines its entire future valuation.
Monthly dynamics of market capitalization of the market segment - Oncology cell gene therapy
Autolus Therapeutics is a biopharmaceutical company specializing in the development of next-generation CAR-T cell therapies for cancer treatment. Its future depends on the success of clinical trials. The cell and gene therapy sector chart will reflect overall investor interest in this revolutionary, yet expensive, area of medicine in which Autolus operates.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Autolus Therapeutics is a leader in cancer cell therapy. The company's shares are steeped in news about clinical trials and drug approvals. Their monthly performance is almost completely disconnected from overall market sentiment. The chart reflects not the economy, but scientific breakthroughs and investor confidence in the future of its technologies.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Autolus Therapeutics
Autolus Therapeutics, a company developing advanced CAR-T cell therapy, is at the forefront of oncology. Its weekly stock price performance is reflecting challenging clinical data and manufacturing updates, creating the high volatility typical of this complex biotech sector.
Weekly dynamics of market capitalization of the market segment - Oncology cell gene therapy
The cancer cell therapy sector, where Autolus operates, is driven by expectations of breakthrough technologies. The chart below reflects the general sentiment in this niche. It helps understand how unique and promising the market perceives Autolus' technology compared to developments by other companies working in the CAR-T therapy field.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Autolus Therapeutics is a company developing cutting-edge CAR-T cell therapy for cancer treatment. Its shares are surrounded by biotech conferences and press releases about trials. The chart will show how much its performance is detached from the broader market and driven solely by scientific events.
Market capitalization of the company, segment and market as a whole
AUTL - Market capitalization of the company Autolus Therapeutics
Autolus Therapeutics' market capitalization reflects investor valuation of its cutting-edge CAR-T cell therapy platform. The chart reflects market confidence in the potential of its programmable immune cells to effectively fight cancer. Its high valuation, despite the lack of commercial products, demonstrates the enormous potential of this revolutionary technology.
AUTL - Share of the company's market capitalization Autolus Therapeutics within the market segment - Oncology cell gene therapy
Autolus Therapeutics is at the forefront of cell-based gene therapy in oncology. Its market capitalization in this cutting-edge segment reflects the potential of its CAR-T technologies. Investors are betting that its innovative blood cancer treatments will be more effective than existing ones and receive regulatory approval.
Market capitalization of the market segment - Oncology cell gene therapy
Here's a chart reflecting the combined weight of the entire biotech sector specializing in cell and gene therapy. For Autolus Therapeutics, which is developing cutting-edge CAR-T therapy, this line represents the scale of its hopes. Its growth is bringing billions of dollars into the industry, enabling the company to conduct high-value research that could transform oncology.
Market capitalization of all companies included in a broad market index - GURU.Markets
Autolus Therapeutics is a pioneer in the development of next-generation CAR-T cell therapy for cancer treatment. Its market capitalization is based on its cutting-edge "living drug" technology. Globally, this represents one of the most complex and promising approaches in oncology.
Book value capitalization of the company, segment and market as a whole
AUTL - Book value capitalization of the company Autolus Therapeutics
Autolus Therapeutics is a company developing advanced cell therapy (CAR-T) for cancer treatment. Its book value is derived from its financial resources and production base: funds for clinical trials and high-tech laboratories. How has this foundation for fighting cancer grown? The chart below shows.
AUTL - Share of the company's book capitalization Autolus Therapeutics within the market segment - Oncology cell gene therapy
Autolus Therapeutics is a pioneer in CAR-T cell therapy. Its technologies require a unique and complex infrastructure: in-house centers for the development and production of customized cancer drugs. The chart shows the company's share of the physical infrastructure required to create this cutting-edge class of oncology drugs.
Market segment balance sheet capitalization - Oncology cell gene therapy
Autolus Therapeutics, a cell therapy company, is a capital-intensive business. This requires the ownership of advanced R&D centers and the construction of its own manufacturing facilities. The BCap_Seg chart for the biotech sector shows that developing breakthrough technologies requires a significant financial base.
Book value of all companies included in the broad market index - GURU.Markets
Autolus Therapeutics' assets are not factories, but cutting-edge laboratories and manufacturing facilities for creating personalized CAR-T cell therapies for cancer treatment. Its balance sheet reflects its unique scientific and technological base. The chart below shows the net worth of this oncology innovator.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Autolus Therapeutics
Autolus's balance sheet consists of its laboratories and R&D capital. Its entire market value is a premium for its cutting-edge CAR-T cancer treatment platform. Its price is a bet by investors that its "living drugs" will be safer and more effective than those of its competitors.
Market to book capitalization ratio in a market segment - Oncology cell gene therapy
Autolus Therapeutics is a company developing advanced cell therapy (CAR-T) for cancer treatment. Its high valuation on this chart reflects investors' faith in its technology, which could offer new treatment options for cancer patients with limited alternatives.
Market to book capitalization ratio for the market as a whole
Autolus Therapeutics develops advanced cell therapy (CAR-T) for cancer treatment. The company's value lies in its scientific platform and clinical trial data. Its market capitalization is a multiple of its book value, reflecting its hopes for a revolution in oncology. The chart demonstrates this belief in the technology.
Debts of the company, segment and market as a whole
AUTL - Company debts Autolus Therapeutics
Autolus Therapeutics, a biopharmaceutical company specializing in CAR-T cell therapy for cancer, is using capital to fund its complex and expensive clinical programs. This chart shows how the company is raising significant funds to advance its personalized treatments, which have the potential to revolutionize oncology.
Market segment debts - Oncology cell gene therapy
Autolus Therapeutics is a company specializing in the development of advanced CAR-T cell therapies for cancer treatment. Creating such complex "living" drugs requires massive investments in R&D and manufacturing. This chart shows how the company finances its expensive development, relying primarily on equity capital, as is typical in this sector.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Autolus Therapeutics
Autolus Therapeutics develops cutting-edge cell therapy for cancer, one of the most capital-intensive areas of biotech. This chart shows how the company finances its expensive research. It's a measure of financial risk: a high debt load means a significant bet on the success and commercial viability of their technology.
Market segment debt to market segment book capitalization - Oncology cell gene therapy
Autolus Therapeutics develops cutting-edge T-cell therapies for cancer. Cell and gene therapy are among the most complex and expensive areas of medicine. The chart shows how aggressively the biotech sector is using debt to finance these revolutionary but capital-intensive technologies, and how Autolus compares against this backdrop.
Debt to book value of all companies in the market
Autolus Therapeutics, a pioneer in cell gene therapy, requires colossal investments in clinical trials and manufacturing. This chart reflects the overall debt burden of the market. It allows us to assess how Autolus's capital raising strategy is typical for biotech companies at the riskiest stages of development.
P/E of the company, segment and market as a whole
P/E - Autolus Therapeutics
Autolus Therapeutics is a biopharmaceutical company developing next-generation CAR-T cell therapies for the treatment of cancer. This chart shows how investors value its cutting-edge technologies. The valuation is based not on current profits, but on clinical trial results and the potential of its drugs to offer better cancer treatment outcomes.
P/E of the market segment - Oncology cell gene therapy
Autolus Therapeutics is developing cutting-edge CAR-T therapy. This chart shows the average valuation for the biotech sector. It serves as a backdrop for Autolus's valuation: investors look not at its profits relative to the industry, but at the potential of its technologies to deliver breakthroughs in cancer treatment, which justifies its high valuation.
P/E of the market as a whole
Autolus Therapeutics is a biopharmaceutical company developing a new generation of programmable T-cell therapies for the treatment of oncology. This chart reflects the overall risk appetite of investors in biotech. It helps us understand whether AUTL's valuation reflects faith in its innovative cell technologies or whether it moves in line with overall sector sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Autolus Therapeutics
Autolus Therapeutics develops cutting-edge cell therapies for cancer treatment. The company's future profitability depends on the success of its complex and expensive clinical trials. This chart reflects investors' confidence that its technology will prove effective and find a niche in cancer treatment.
%20P%2FE%20Autolus%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Autolus-Therapeutics&v=1772609959336 "Chart of the company's future (projected) P/E Autolus Therapeutics")
Future (projected) P/E of the market segment - Oncology cell gene therapy
Autolus Therapeutics is a company specializing in the development of next-generation CAR-T cell therapies for the treatment of oncology. The data here reflects the collective analyst consensus on the success of its clinical programs. It is a barometer of expectations that its technologies will offer superior outcomes or safety compared to existing therapies.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-cell-gene-therapy&v=1772609959338 "Future (projected) P/E graph of the market segment - Oncology cell gene therapy")
Future (projected) P/E of the market as a whole
Autolus Therapeutics develops cutting-edge cell therapies for cancer treatment. Their technologies have the potential to transform approaches to oncology. This sentiment chart is important because it reflects investor willingness to fund capital-intensive biotech companies whose products require lengthy and expensive clinical trials.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772609959340 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Autolus Therapeutics
Autolus Therapeutics is a company specializing in the development of cutting-edge CAR-T cell therapy for the treatment of cancer. This chart illustrates the high cost of medical innovation. It reflects investments in complex clinical trials, the success of which could lead to the development of a powerful new weapon in the fight against cancer.
Profit of companies in the market segment - Oncology cell gene therapy
Autolus Therapeutics is a biopharmaceutical company specializing in the development of advanced cell-based gene therapy for cancer treatment. Its CAR-T technology represents a breakthrough in oncology. Currently in the clinical stage, the company is investing in the future, and its potential profitability depends on the success of trials, which is typical for this innovative segment.
Overall market profit
Autolus Therapeutics is a company specializing in the development of advanced cell therapies for cancer treatment. Its future depends on successful clinical trials and regulatory approval. The overall economic situation, reflected in this chart, doesn't affect the demand for its drugs, but it does impact the financial markets on which its costly operations rely.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Autolus Therapeutics
Autolus Therapeutics is a biopharmaceutical company specializing in the development of CAR-T cell therapies for the treatment of cancer. This chart reflects analysts' speculative earnings expectations. The forecast is entirely dependent on the results of clinical trials and potential approval of their cutting-edge cancer treatments.
%20profit%20of%20the%20company%20Autolus%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Autolus-Therapeutics&v=1772609959349 "Graph of future (projected) profit of the company Autolus Therapeutics")
Future (predicted) profit of companies in the market segment - Oncology cell gene therapy
Autolus Therapeutics is a company at the forefront of oncology, developing next-generation CAR-T cell therapy. The sector's revenue projections, shown in the graph, reflect the high hopes for personalized cancer treatment. This chart helps assess how Autolus' technology could be safer and more effective than existing methods.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-cell-gene-therapy&v=1772609959362 "Graph of future (predicted) profits of companies in a market segment - Oncology cell gene therapy")
Future (predicted) profit of the market as a whole
Autolus Therapeutics is a biopharmaceutical company specializing in the development of CAR-T cell therapy for cancer treatment. This is a cutting-edge, but expensive, technology. Funding for its development and future implementation depend on the investment climate and healthcare budgets, which are influenced by the overall economic situation, as reflected in this chart.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772609959373 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Autolus Therapeutics
Autolus Therapeutics is a company developing cutting-edge CAR-T cell therapy for cancer. It may not have commercial revenue. This chart shows how highly investors value its potential, betting that its personalized treatments will revolutionize oncology.
P/S market segment - Oncology cell gene therapy
Autolus Therapeutics is a biopharmaceutical company specializing in the development of next-generation programmable T-cell therapies for the treatment of oncology. This chart shows the average revenue estimate for the biotech sector. It helps understand how highly the market values the potential of Autolus's innovative platform.
P/S of the market as a whole
Autolus Therapeutics is a biopharmaceutical company specializing in the development of next-generation CAR-T cell therapies for cancer treatment. The company's technologies are aimed at improving the efficacy and safety of treatments. This chart helps understand how the market values companies with established revenues, which is important for contextualizing the analysis of advanced biotech.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Autolus Therapeutics
Autolus Therapeutics is a company specializing in the development of next-generation CAR-T cell therapies for cancer treatment. This chart reflects investors' high estimates of its potential future revenues. This valuation is a bet on the clinical and commercial success of its innovative approaches to cancer treatment.
%20P%2FS%20Autolus%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Autolus-Therapeutics&v=1772609959387 "The graph of the company's future (projected) P/S Autolus Therapeutics")
Future (projected) P/S of the market segment - Oncology cell gene therapy
Autolus Therapeutics is a biopharmaceutical company developing next-generation CAR-T cell therapy for the treatment of cancer. This chart compares market expectations for its future revenue with those of its competitors. This valuation reflects investor expectations that its innovative approaches will lead to safer and more effective cancer treatments.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-cell-gene-therapy&v=1772609959388 "Future (projected) P/S market segment graph - Oncology cell gene therapy")
Future (projected) P/S of the market as a whole
Autolus Therapeutics is a biotechnology company specializing in the development of advanced CAR-T cell therapy for cancer treatment. Its success depends entirely on clinical trial results and regulatory approval. This overall revenue expectation schedule is irrelevant for Autolus, whose value is created in laboratories and clinics, not in the overall market.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772609959389 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Autolus Therapeutics
This chart shows the revenue of Autolus Therapeutics, a company working at the forefront of oncology with CAR-T cell therapy. The company has no commercial clinical-stage sales, so any revenue it has comes from partnerships with major pharmaceutical companies. The chart emphasizes that the company's valuation is based not on current revenue, but on the potential of its innovative therapeutic platform.
Sales of companies in the market segment - Oncology cell gene therapy
Autolus Therapeutics is a biopharmaceutical company at the forefront of cancer cell therapy. It is developing a new generation of programmable T-cell therapies (CAR-T) for the treatment of oncology. This chart shows revenue in the cell and gene therapy oncology sector. It reflects the revolution in cancer treatment, where Autolus strives to create safer and more effective "living" drugs.
Overall market sales
Autolus Therapeutics is developing cutting-edge CAR-T cell therapy for cancer treatment. Its success depends on clinical trial results and regulatory approval. This overall economic activity schedule doesn't directly impact its operations, but the overall growth in wealth provides long-term funding for healthcare innovation.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Autolus Therapeutics
Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of advanced CAR-T cell therapies for cancer treatment. This projected revenue chart reflects high expectations for its scientific developments. The growth is driven by expectations for successful clinical trial results and the potential commercial launch of its drugs.
%20sales%20of%20the%20company%20Autolus%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Autolus-Therapeutics&v=1772609959391 "Schedule of future (projected) sales of the company Autolus Therapeutics")
Future (projected) sales of companies in the market segment - Oncology cell gene therapy
Autolus Therapeutics is a biopharmaceutical company specializing in the development of next-generation CAR-T cell therapies for the treatment of cancer. Their goal is to create safer and more effective "living" drugs. This chart shows projected revenue for the oncology cell therapy sector, reflecting the race to create breakthrough cancer treatments.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-cell-gene-therapy&v=1772609959403 "Schedule of future (projected) sales of companies in the market segment - Oncology cell gene therapy")
Future (projected) sales of the market as a whole
Autolus Therapeutics develops cutting-edge cell therapy methods for cancer treatment. The company's success depends on clinical results and regulatory approval. The overall economic situation affects the ability of healthcare systems to afford expensive, innovative treatments, so stable economic growth is an important background factor.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772609959404 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Autolus Therapeutics
Autolus Therapeutics is at the forefront of cancer cell therapy, focusing on developing sophisticated and personalized treatments. This graph reflects the enormous investment required to advance such technologies through clinical trials. This is the price the company is paying for a potential revolution in oncology.
Market segment marginality - Oncology cell gene therapy
Autolus Therapeutics is a biopharmaceutical company specializing in the development of next-generation CAR-T cell therapies for the treatment of oncology. The data in the chart reflects its financial performance relative to other players in the sector. Its outperformance may be due to advance payments from clinical development partners.
Market marginality as a whole
Autolus Therapeutics is a company specializing in the development of cutting-edge CAR-T cell therapy for cancer treatment. Its value is determined not by the economic situation, as shown in this chart, but by progress in clinical trials. Success in developing effective and safe cancer treatments can lead to breakthroughs, regardless of external economic factors.
Employees in the company, segment and market as a whole
Number of employees in the company Autolus Therapeutics
Autolus Therapeutics is a clinical-stage company specializing in the development of cutting-edge CAR-T cell therapy for cancer treatment. This chart shows the company's growing team of scientists. The increase in staff directly reflects investment in this complex technology, progress in clinical trials, and preparations for a potential commercial launch.
Share of the company's employees Autolus Therapeutics within the market segment - Oncology cell gene therapy
Autolus Therapeutics develops cutting-edge cell therapies for cancer treatment. The creation and production of such complex "living drugs" requires a large and highly specialized team of scientists and technicians. This chart shows its investment in human capital, reflecting its share of the talent pool working at the forefront of oncology research.
Number of employees in the market segment - Oncology cell gene therapy
Autolus Therapeutics is a biotechnology company specializing in the development of cutting-edge CAR-T cell therapy for the treatment of cancer. This graph demonstrates the complexity and research intensity of this breakthrough medical field. The growing number of scientists and manufacturing specialists reflects progress in clinical trials and preparations for the commercialization of this complex therapy.
Number of employees in the market as a whole
Autolus Therapeutics is a biopharmaceutical company developing cutting-edge cell gene therapy for cancer treatment. Its staff includes highly specialized researchers and clinicians. This employment chart demonstrates that the advanced biotechnology sector creates unique jobs, the growth of which is driven by scientific advancement rather than general economic cycles.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Autolus Therapeutics (AUTL)
Autolus Therapeutics is a biopharmaceutical company specializing in the development of next-generation CAR-T cell therapy for cancer treatment. It's at the forefront of oncology. This chart demonstrates the enormous value created by each scientist. High values are typical for biotech, where market capitalization reflects investors' faith in a breakthrough technology and the future revenues from its application.
%20of%20the%20company%20Autolus%20Therapeutics%20(AUTL)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Autolus-Therapeutics-AUTL&v=1772609959435 "Chart of market capitalization per employee (in thousands of dollars) of the company Autolus Therapeutics (AUTL)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy
Autolus Therapeutics is a biopharmaceutical company specializing in the development of cell-based gene therapy for cancer treatment. In this cutting-edge field of medicine, value is determined by scientific breakthroughs. This chart shows the significant premium the market is willing to pay for the intellectual capital and development potential of a small team of scientists compared to other biotech companies.
%20by%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-cell-gene-therapy&v=1772609959444 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology cell gene therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Autolus Therapeutics is developing cutting-edge cell therapy for cancer treatment. This figure illustrates the high value of scientific innovation in oncology. The company's market capitalization is based on the potential of its CAR-T platform. The efforts of a small team of scientists can lead to the creation of a revolutionary treatment, which is what the market values.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772609959445 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Autolus Therapeutics (AUTL)
Autolus Therapeutics is a biotech company specializing in CAR-T cancer therapy. This is one of the most advanced and complex areas of medicine. They are currently in the clinical stage. This graph shows the loss per employee. This reflects the enormous cost of R&D in the field of cell engineering, where every scientist works at the cutting edge of science.
%20Chart%20Autolus%20Therapeutics%20(AUTL)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Autolus-Therapeutics-AUTL&v=1772609959449 "Company Profit Per Employee (in thousands of dollars) Chart Autolus Therapeutics (AUTL)")
Profit per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy
Autolus Therapeutics is a biotech company working in the highly complex field of cell therapy (CAR-T) for cancer treatment. This is cutting-edge science with enormous costs. This metric reflects their R&D budget burn per employee, which is likely above average due to the high cost of developing and manufacturing cell-based products.
%20in%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-cell-gene-therapy&v=1772609959454 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Autolus Therapeutics is a pioneer in cell-based gene therapy for cancer treatment. This is one of the most complex and expensive areas in biotech. The negative profit per employee is enormous, reflecting the colossal cost of R&D, maintaining high-tech labs, and hiring unique specialists to develop "living" drugs.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772609959455 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Autolus Therapeutics (AUTL)
Autolus Therapeutics is a biopharmaceutical company specializing in the development of advanced CAR-T cell therapy for cancer treatment. This chart shows the company's business at the clinical trial stage. No revenue per employee is normal for a company whose value lies in the potential of its innovative platform.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Autolus-Therapeutics-AUTL&v=1772609959456 "Sales chart per company employee Autolus Therapeutics (AUTL)")
Sales per employee in the market segment - Oncology cell gene therapy
Autolus (AUTL) is a biotech company specializing in the development of next-generation CAR-T cell therapies for cancer. This chart shows how much revenue (from partnerships) each employee (scientist) generates. This indicates the effectiveness of their sophisticated cell engineering R&D platform compared to other oncology biotechs.
Sales per employee for the market as a whole
Autolus Therapeutics is a biopharmaceutical company specializing in the development of next-generation CAR-T cell therapies for the treatment of cancer. This is a highly complex R&D process. The company does not yet have commercial products. This metric does not reflect current efficacy but represents a starting point for the potential commercialization of their therapy.
Short shares by company, segment and market as a whole
Shares shorted by company Autolus Therapeutics (AUTL)
Autolus Therapeutics is a biotech company developing advanced CAR-T cell therapies for cancer treatment. This chart measures bearish bets. Bears fear the extreme complexity and expense of manufacturing such treatments, as well as the risk of clinical failure or competition from larger players.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Autolus-Therapeutics-AUTL&v=1772609959458 "Short Shares Chart for the Company Autolus Therapeutics (AUTL)")
Shares shorted by market segment - Oncology cell gene therapy
Autolus Therapeutics is developing CAR-T therapy—a "living" drug for cancer treatment. It's a cutting-edge but complex technology. This chart shows bearish bets. "Shorts" here are bets that their therapy will prove too difficult to manufacture, unsafe, or lose out to competitors in the race.
Shares shorted by the overall market
Autolus Therapeutics is a leader in CAR-T cell therapy, which programs a patient's own cells to fight cancer. This is the medicine of the future. This chart shows the overall level of fear in the market. Biotech stocks often live their own lives, reacting to FDA news, but when panic sets in, even revolutionary technologies are not spared from the sell-off.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Autolus Therapeutics (AUTL)
Autolus Therapeutics is a biotech company specializing in CAR-T therapy. It's one of the most advanced and speculative technologies. This chart can soar above 70 on positive R&D news. Oversold territory (<30) often reflects setbacks, delays, production issues, or general investor risk aversion.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Autolus-Therapeutics-AUTL&v=1772609959475 "RSI 14 indicator chart for the company's stock Autolus Therapeutics (AUTL)")
RSI 14 Market Segment - Oncology cell gene therapy
Autolus (AUTL) is a "CAR-T" biotech. They reprogram (engineer) a patient's immune cells (T-cells) to attack blood cancer. The RSI_14_Seg for "Oncology" (biotech) shows the overall sentiment. It helps us understand: is AUTL's volatility due to their R&D or is the entire sector overheated?
RSI 14 for the overall market
Autolus (AUTL) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast AUTL (Autolus Therapeutics)
Autolus (AUTL) is a biotech company developing next-generation advanced CAR-T cell therapy for the treatment of blood cancers. This chart shows the average 12-month forecast, reflecting analysts' confidence in the company's technology platform and its potential for treating lymphoma.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-AUTL-Autolus-Therapeutics&v=1772609959515 "A chart showing analyst consensus forecasts for the expected stock price. AUTL (Autolus Therapeutics)")
The difference between the consensus estimate and the actual stock price AUTL (Autolus Therapeutics)
Autolus is a biotech company working at the cutting edge of oncology—in the field of CAR-T cell therapy. They reprogram patients' T cells to attack cancer. This chart reflects analysts' speculative expectations for their sophisticated R&D platform and their leading lymphoma treatment candidate.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-AUTL-Autolus-Therapeutics&v=1772609959533 "A chart showing the difference between the consensus forecast and the actual stock price. AUTL (Autolus Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Oncology cell gene therapy
Autolus Therapeutics is a biotech company developing "living drugs" (CAR-T therapies) for cancer treatment. This is at the cutting edge of science. This chart shows analysts' overall expectations for the entire cell and gene therapy sector. It reflects whether experts believe these complex and expensive treatments will be commercially successful.
Analysts' consensus forecast for the overall market share price
Autolus Therapeutics (AUTL) is a clinical-stage biopharmaceutical company working at the forefront of CAR-T therapy. They "reprogram" patients' T cells to fight blood cancers. This chart shows the company's overall risk appetite, reflecting investors' willingness to fund breakthrough, but extremely expensive, cancer treatments.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Autolus Therapeutics
Autolus is a late-stage biotech company working at the forefront of oncology: CAR-T therapy. These are living drugs that reprogram a patient's cells to attack cancer. This graph is a barometer of their science. It likely reflects their progress in clinical trials, their manufacturing know-how, and the market's confidence in their next-generation CAR-T therapy.
AKIMA Market Segment Index - Oncology cell gene therapy
Autolus (AUTL) is a clinical-stage biotech and a pioneer in CAR-T therapy; the UK-based company is developing a new generation of programmable cell therapies for the treatment of blood cancers. This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does this breakthrough (CAR-T) R&D platform (AUTL) differentiate it from the average pharma company?
The AKIM Index for the overall market
Autolus is a biopharmaceutical company developing programmable T-cell therapies (CAR-T) for the treatment of blood cancer (leukemia). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this innovative cell therapy, which is approaching commercialization, compares to overall economic trends.
